10.1111/dom.16364 Summary Keywords tirzepatide, rhabdomyolysis, GLP-1 receptor agonist, adverse drug reaction, muscle injury Citation Bodanowitz JM, Mattes I, Loebermann M and Fritzsche C (2025) Case Report: Rhabdomyolysis following initiation of tirzepatide
However, its clinical utility is limited due to rapid enzymatic breakdown
Truveta Research study : At 52 weeks, weight loss was 18.2% for Mounjaro (tirzepatide ADM) compared to 10.6% for Ozempic (semaglutide ADM) for patients without type 2 diabetes (T2D) The lower percentages in the Truveta Research study likely reflect a shorter timeframe (52 weeks instead of 72) and the use of ADM versions, which can have lower doses
FV), CM and SG PhD fellowship grants were awarded from the Italian Ministry of Education, University and Research
(7) Contraindications and side effects: Pyridostigmine is contraindicated in mechanical intestinal or urinary obstruction